BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

593 related articles for article (PubMed ID: 28317403)

  • 1. Intrahepatic cholangiocarcinoma: current management and emerging therapies.
    Rahnemai-Azar AA; Weisbrod AB; Dillhoff M; Schmidt C; Pawlik TM
    Expert Rev Gastroenterol Hepatol; 2017 May; 11(5):439-449. PubMed ID: 28317403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular profiling of intrahepatic cholangiocarcinoma: the search for new therapeutic targets.
    Oliveira DV; Zhang S; Chen X; Calvisi DF; Andersen JB
    Expert Rev Gastroenterol Hepatol; 2017 Apr; 11(4):349-356. PubMed ID: 28162004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrahepatic cholangiocarcinoma: Molecular markers for diagnosis and prognosis.
    Rahnemai-Azar AA; Weisbrod A; Dillhoff M; Schmidt C; Pawlik TM
    Surg Oncol; 2017 Jun; 26(2):125-137. PubMed ID: 28577718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular genetics and targeted therapeutics in biliary tract carcinoma.
    Marks EI; Yee NS
    World J Gastroenterol; 2016 Jan; 22(4):1335-47. PubMed ID: 26819503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging pathways for precision medicine in management of cholangiocarcinoma.
    Rahnemai-Azar AA; Abbasi A; Acher AW; Weber SM; Pawlik TM
    Surg Oncol; 2020 Dec; 35():47-55. PubMed ID: 32827952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene alterations and epigenetic changes in intrahepatic cholangiocarcinoma.
    Huang SB; Zheng CX
    Expert Rev Anticancer Ther; 2017 Jan; 17(1):89-96. PubMed ID: 27893290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and cytogenomic profiling of hepatic adenocarcinoma expressing inhibinA, a mimicker of neuroendocrine tumors: proposal to reclassify as "cholangioblastic variant of intrahepatic cholangiocarcinoma".
    Braxton DR; Saxe D; Damjanov N; Stashek K; Shroff S; Morrissette JD; Tondon R; Furth EE
    Hum Pathol; 2017 Apr; 62():232-241. PubMed ID: 28232156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges of surgical management of intrahepatic cholangiocarcinoma.
    Squires MH; Cloyd JM; Dillhoff M; Schmidt C; Pawlik TM
    Expert Rev Gastroenterol Hepatol; 2018 Jul; 12(7):671-681. PubMed ID: 29911912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Narrative review: current management and novel targeted therapies in intrahepatic cholangiocarcinoma.
    Bath NM; Pawlik TM
    Chin Clin Oncol; 2023 Feb; 12(1):5. PubMed ID: 36922354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?
    Aitcheson G; Mahipal A; John BV
    Expert Opin Investig Drugs; 2021 Apr; 30(4):463-477. PubMed ID: 33678096
    [No Abstract]   [Full Text] [Related]  

  • 11. Systemic treatment of advanced or recurrent biliary tract cancer.
    Zhang W; Zhou H; Wang Y; Zhang Z; Cao G; Song T; Zhang T; Li Q
    Biosci Trends; 2020 Nov; 14(5):328-341. PubMed ID: 32830166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma.
    Zhang R; Li Q; Fu J; Jin Z; Su J; Zhang J; Chen C; Geng Z; Zhang D
    BMC Cancer; 2021 Feb; 21(1):112. PubMed ID: 33535978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholangiocarcinoma: molecular pathways and therapeutic opportunities.
    I Ilyas S; Borad MJ; Patel T; Gores GJ
    Semin Liver Dis; 2014 Nov; 34(4):456-64. PubMed ID: 25369307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Pathogenesis and Current Therapy in Intrahepatic Cholangiocarcinoma.
    Høgdall D; O'Rourke CJ; Taranta A; Oliveira DV; Andersen JB
    Dig Dis; 2016; 34(4):440-51. PubMed ID: 27170400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coming of a precision era of the staging systems for intrahepatic cholangiocarcinoma?
    Cheng Z; Lei Z; Shen F
    Cancer Lett; 2019 Sep; 460():10-17. PubMed ID: 31212000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current challenges to underpinning the genetic basis for cholangiocarcinoma.
    Cigliano A; Chen X; Calvisi DF
    Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):511-526. PubMed ID: 33888034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma.
    Moeini A; Sia D; Bardeesy N; Mazzaferro V; Llovet JM
    Clin Cancer Res; 2016 Jan; 22(2):291-300. PubMed ID: 26405193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New insights into the molecular pathogenesis of intrahepatic cholangiocarcinoma.
    Patel T
    J Gastroenterol; 2014 Feb; 49(2):165-72. PubMed ID: 24145988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting cholangiocarcinoma.
    Mertens JC; Ilyas SI; Gores GJ
    Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1454-1460. PubMed ID: 28844952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver transplantation as an alternative for the treatment of intrahepatic cholangiocarcinoma: Past, present, and future directions.
    Kodali S; Connor AA; Thabet S; Brombosz EW; Ghobrial RM
    Hepatobiliary Pancreat Dis Int; 2024 Apr; 23(2):129-138. PubMed ID: 37517983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.